3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Recurrence
2
Carcinoma, Non-Small-Cell Lung
2
Virus Diseases
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Influenza, Human
1
Head and Neck Neoplasms
1
Ganglioneuroblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
B-cell Malignancies
1
Interventions
Pemetrexed
13
Cisplatin
12
Nivolumab
5
Carboplatin
5
pembrolizumab
4
Ipilimumab
4
Cyclophosphamide
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
fludarabine
3
defactinib
3
amatuximab
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
tremelimumab
1
tazemetostat
1
osimertinib
1
napabucasin
1
enzalutamide
1
bemcentinib
1
abemaciclib
1
VS-5584
1
Trabectedin
1
Thiostrepton
1
Safety
1
Panobinostat
1
Monatide (IMS 3015)
1
Midazolam
1
Letrozole
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma, Malignant
×
Influenza Vaccines
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled